Cargando…

High penetrances of BRCA1 and BRCA2 mutations confirmed in a prospective series

Penetrances of BRCA1 and BRCA2 mutations have been derived from retrospective studies, implying the possibility of ascertainment biases to influence the results. We have followed women at risk for breast and/or ovarian cancer for two decades, and report the prospectively observed age-related annual...

Descripción completa

Detalles Bibliográficos
Autores principales: Møller, Pål, Mæhle, Lovise, Engebretsen, Lars F, Ludvigsen, Trond, Jonsrud, Christoffer, Apold, Jaran, Vabø, Anita, Clark, Neal
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2828412/
https://www.ncbi.nlm.nih.gov/pubmed/20180971
http://dx.doi.org/10.1186/1897-4287-8-2
_version_ 1782178002255216640
author Møller, Pål
Mæhle, Lovise
Engebretsen, Lars F
Ludvigsen, Trond
Jonsrud, Christoffer
Apold, Jaran
Vabø, Anita
Clark, Neal
author_facet Møller, Pål
Mæhle, Lovise
Engebretsen, Lars F
Ludvigsen, Trond
Jonsrud, Christoffer
Apold, Jaran
Vabø, Anita
Clark, Neal
author_sort Møller, Pål
collection PubMed
description Penetrances of BRCA1 and BRCA2 mutations have been derived from retrospective studies, implying the possibility of ascertainment biases to influence the results. We have followed women at risk for breast and/or ovarian cancer for two decades, and report the prospectively observed age-related annual incidence rates to contract breast or ovarian cancer for women with deleterious BRCA1 or BRCA2 mutations based on 4830 observation years. Patients were grouped according to mutation, age and having/not having had previous cancer. In women not having had previous cancer and aged 40-59 years, the annual incidence rate to contract breast or ovarian cancer in those having the most frequent BRCA1 founder mutations was 4.0%, for women in this age group and with less frequent BRCA1 mutations annual incidence rate was 5.9%, and for women with BRCA2 mutations 3.5%. The observed figures may be used for genetic counseling of healthy mutation carriers in the respective age groups. The results may indicate that less frequent BRCA1 mutations have higher penetrances than BRCA1 founder mutations.
format Text
id pubmed-2828412
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-28284122010-02-25 High penetrances of BRCA1 and BRCA2 mutations confirmed in a prospective series Møller, Pål Mæhle, Lovise Engebretsen, Lars F Ludvigsen, Trond Jonsrud, Christoffer Apold, Jaran Vabø, Anita Clark, Neal Hered Cancer Clin Pract Research Penetrances of BRCA1 and BRCA2 mutations have been derived from retrospective studies, implying the possibility of ascertainment biases to influence the results. We have followed women at risk for breast and/or ovarian cancer for two decades, and report the prospectively observed age-related annual incidence rates to contract breast or ovarian cancer for women with deleterious BRCA1 or BRCA2 mutations based on 4830 observation years. Patients were grouped according to mutation, age and having/not having had previous cancer. In women not having had previous cancer and aged 40-59 years, the annual incidence rate to contract breast or ovarian cancer in those having the most frequent BRCA1 founder mutations was 4.0%, for women in this age group and with less frequent BRCA1 mutations annual incidence rate was 5.9%, and for women with BRCA2 mutations 3.5%. The observed figures may be used for genetic counseling of healthy mutation carriers in the respective age groups. The results may indicate that less frequent BRCA1 mutations have higher penetrances than BRCA1 founder mutations. BioMed Central 2010-01-19 /pmc/articles/PMC2828412/ /pubmed/20180971 http://dx.doi.org/10.1186/1897-4287-8-2 Text en Copyright ©2010 Møller et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Møller, Pål
Mæhle, Lovise
Engebretsen, Lars F
Ludvigsen, Trond
Jonsrud, Christoffer
Apold, Jaran
Vabø, Anita
Clark, Neal
High penetrances of BRCA1 and BRCA2 mutations confirmed in a prospective series
title High penetrances of BRCA1 and BRCA2 mutations confirmed in a prospective series
title_full High penetrances of BRCA1 and BRCA2 mutations confirmed in a prospective series
title_fullStr High penetrances of BRCA1 and BRCA2 mutations confirmed in a prospective series
title_full_unstemmed High penetrances of BRCA1 and BRCA2 mutations confirmed in a prospective series
title_short High penetrances of BRCA1 and BRCA2 mutations confirmed in a prospective series
title_sort high penetrances of brca1 and brca2 mutations confirmed in a prospective series
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2828412/
https://www.ncbi.nlm.nih.gov/pubmed/20180971
http://dx.doi.org/10.1186/1897-4287-8-2
work_keys_str_mv AT møllerpal highpenetrancesofbrca1andbrca2mutationsconfirmedinaprospectiveseries
AT mæhlelovise highpenetrancesofbrca1andbrca2mutationsconfirmedinaprospectiveseries
AT engebretsenlarsf highpenetrancesofbrca1andbrca2mutationsconfirmedinaprospectiveseries
AT ludvigsentrond highpenetrancesofbrca1andbrca2mutationsconfirmedinaprospectiveseries
AT jonsrudchristoffer highpenetrancesofbrca1andbrca2mutationsconfirmedinaprospectiveseries
AT apoldjaran highpenetrancesofbrca1andbrca2mutationsconfirmedinaprospectiveseries
AT vabøanita highpenetrancesofbrca1andbrca2mutationsconfirmedinaprospectiveseries
AT clarkneal highpenetrancesofbrca1andbrca2mutationsconfirmedinaprospectiveseries